Abstract:

Objective　To observe the clinical efficacy of modified Xiao Jianzhong decoction for patients with centrally mediated abdominal pain syndrome (CAPS) of spleen and stomach deficiency-cold type. Methods　Sixty-eight patients with CAPS of spleen and stomach deficiency-cold type treated at Baoji Chencang Hospital from September 2021 to August 2023 were selected for the randomized controlled trial, and were divided into a control group and an observation group by the random number table method, with 34 cases in each group. There were 18 males and 16 females in the control group; they were (49.97±9.35) years old; their disease course was from 6 months to 8 years. There were 15 males and 19 females in the observation group; they were (51.68±11.83) years old; their disease course was from 6 months to 10 years. The control group were given routine clinical treatment, such as regulating intestinal function, antispasmodic, probiotics to regulate intestinal flora, etc. and took doxorubicin for anxiolytic treatment. The observation group took Xiao Jianzhong decoction. The scores of pain scale and Hamilton Anxiety Scale (HAMA), life quality, therapeutic effects, and adverse reactions were compared between the two groups. t and χ² tests were used for the statistical analysis. Results　After 4 weeks' treatment, the scores of pain scale and HAMA in the observation group were lower than those in the control group (2.47±0.83 vs. 4.03±1.00 and 6.26±2.26 vs. 9.21±2.19; both P<0.05). The effective rate in the observation group was higher than that in the control group [94.12% (32/34) vs. 73.53% (25/34); P=0.021]. The incidence rate of adverse reactions in the observation group was lower than that in the control group [17.65% (6/34) vs. 76.47% (26/34); P<0.05]. The score of life quality in the observation group was higher than that in the control group (88.94±1.59 vs. 79.56±2.05; P<0.05). Conclusion　Modified Xiao Jianzhong decoction for patients with CAPS of spleen and stomach deficiency-cold type can effectively alleviate their symptoms, improve their life quality, with better overall effectiveness and a lower incidence rate of adverse reactions.

Key words:

Spleen and stomach deficiency-cold type, Centrally mediated abdominal pain syndrome, Xiao Jianzhong decoction, Depression,  , Therapeutic effect

摘要：

目的　观察小建中汤加味治疗脾胃虚寒型中枢介导的腹痛综合征（centrally mediated abdominal pain syndrome，CAPS）的临床效果。方法　选取宝鸡市陈仓医院2021年9月至2023年8月收治的68例脾胃虚寒型CAPS患者进行随机对照试验。采用随机数字表法将其分为对照组和观察组，各34例。对照组男18例，女6例，年龄（49.97±9.35）岁，病程6个月～8年；观察组男15例，女19例，年龄（51.68±11.83）岁，病程6个月～10年。对照组予以调节肠功能、解痉、益生菌调节肠道菌群等常规临床治疗，并加用多塞平抗焦虑治疗。观察组给予小建中汤加味治疗。比较两组疼痛量表评分、汉密顿焦虑量表（Hamilton Anxiety Scale，HAMA）评分、生活质量、治疗效果及用药不良反应。采用t检验、χ²检验进行统计分析。结果　治疗4周后，观察组疼痛量表评分、HAMA评分均低于对照组［（2.47±0.83）分比（4.03±1.00）分、（6.26±2.26）分比（9.21±2.19）分，均P<0.05］。观察组有效率高于对照组［94.12%（32/34）比73.53%（25/34），P=0.021］。观察组不良反应发生率低于对照组［17.65%（6/34）比76.47%（26/34），P<0.05］。观察组生活质量评分高于对照组［（88.94±1.59）分比（79.56±2.05）分，P<0.05］。结论　小建中汤加味治疗脾胃虚寒型CAPS患者能有效减轻其症状，改善患者生活质量，总体疗效更好，并且不良反应发生率较低。

关键词:

脾胃虚寒型, 中枢介导的腹痛综合征, 小建中汤, 郁证, 治疗效果